Clinical Trials Logo
  1. Home
  2. Cervical Carcinoma
  3. NCT02523365

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma

Cervical Carcinoma Clinical Trial

Official title:
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma: Clinical Trial

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for cervical carcinoma.

Clinical Trial Description

By enrolling patients with cervical carcinoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for cervical carcinoma. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02523365
Study type Interventional
Source Fuda Cancer Hospital, Guangzhou
Contact
Status Completed
Phase Phase 1/Phase 2
Start date May 2015
Completion date August 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT05458869 - Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
Not yet recruiting NCT04483557 - Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility Phase 2
Terminated NCT04099277 - A Study of LY3435151 in Participants With Solid Tumors Phase 1
Recruiting NCT04452526 - I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination N/A
Active, not recruiting NCT04443296 - Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma Phase 1
Recruiting NCT05180851 - Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study Early Phase 1
Withdrawn NCT03220009 - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Phase 2
Completed NCT02460237 - HPV Self-Test Intervention in Ohio Appalachia N/A
Terminated NCT00924066 - Ixabepilone to Treat Cervical Cancer Phase 2
Completed NCT04208724 - Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization N/A
Completed NCT03307044 - Fractional CO2 Laser Therapy for Survivors of Breast Malignancies N/A
Recruiting NCT05139368 - Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer N/A
Completed NCT03180294 - Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Phase 2
Recruiting NCT05366478 - A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors Phase 1
Completed NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Terminated NCT03345784 - Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Phase 1
Completed NCT03372720 - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors N/A
Active, not recruiting NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Phase 1
Active, not recruiting NCT00867464 - Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
Recruiting NCT06241235 - Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma Phase 1/Phase 2